177Lu-Dotatate versus high-dose long-acting octreotide for the treatment of patients with advanced, grade 1-2, well-differentiated gastroenteropancreatic neuroendocrine tumours (XT-XTR008-3-01): an open-label, randomised, phase III trial [0.03%]
用于治疗晚期、1-2级分化良好的胃肠胰神经内分泌肿瘤患者的177Lu-Dotatate与高剂量长效奥曲肽的对比三期开放标签随机临床试验(XT-XTR008-3-01)
J Xu,J Chen,S Song et al.
J Xu et al.
Background: The phase III trial, XT-XTR008-3-01, was a randomised controlled trial (RCT) that evaluated the efficacy and safety of XTR008, a novel no-carrier-added lutetium-177 (177Lu)-Dotatate, for the first time in a la...
Palbociclib with adjuvant endocrine therapy in early breast cancer: five-year follow up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13) [0.03%]
帕博西利联合辅助内分泌治疗早期乳腺癌：全球多中心、开放标签、随机III期PALLAS试验(ABCSG-42/AFT-05/PrE0109/BIG-14-13)五年随访分析
E L Mayer,D Hlauschek,M Gnant et al.
E L Mayer et al.
Background: In the phase III PALLAS trial, the addition of two years of palbociclib to adjuvant endocrine therapy (ET) did not improve short-term invasive disease-free survival (iDFS) compared with ET alone in high-risk e...
Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial [0.03%]
一项针对晚期尿路上皮癌一线治疗的二期临床试验：六周期与三周期以铂类药物为基础的化疗后序贯阿维鲁单抗维持治疗（DISCUS）
T Powles,S A Hussain,M A Climent et al.
T Powles et al.
Background: Six cycles of platinum-based chemotherapy followed by avelumab continues to be used in some circumstances in advanced/metastatic urothelial cancer (mUC). To investigate whether shorter chemotherapy duration im...
Combination with BCG induction and maintenance therapy for high-risk non-muscle invasive bladder cancer [0.03%]
卡介苗诱导维持疗法治疗高危非肌层浸润性膀胱癌的疗效与安全性
J J Meeks,T Powles
J J Meeks
Long-term Outcomes with Adjuvant CDK4/6 Inhibitors: Who Benefits Most? [0.03%]
长期使用辅助CDK4/6抑制剂：谁是最大受益者？
T A O&#x;Meara,H J Burstein
T A O&#x;Meara
S Johnston,M Martin,J O&#x;Shaughnessy et al.
S Johnston et al.
Background: Adjuvant abemaciclib combined with endocrine therapy (ET) significantly improved invasive disease-free survival (IDFS) in patients with hormone receptor-positive (HR+), human epidermal growth factor 2-negative...
Personalised Antiemetic Prophylaxis with NEPA for Patients at High-Risk of Chemotherapy-induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: Results from the Randomised, Multinational MyRisk Trial [0.03%]
针对接受中度致吐性化疗的高风险化学治疗引起的恶心和呕吐患者使用NEPA个性化止吐预防：来自MyRisk随机多国试验结果
A Molassiotis,K Jordan,M Karthaus et al.
A Molassiotis et al.
Background: Patients receiving moderately emetogenic chemotherapy (MEC) are commonly prescribed a 5-HT3 receptor antagonist (RA) and dexamethasone (DEX) as standard of care (SOC) antiemetic prophylaxis. However, in patien...
TRADE: A phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/HER2- breast cancer [0.03%]
ABEMACILIB 联合内分泌治疗早期HR阳性/HER2阴性乳腺癌的II期剂量递增试验（TRADING研究）
E L Mayer,D Trapani,S-E Kim et al.
E L Mayer et al.
Purpose: Adjuvant abemaciclib with endocrine therapy (ET) improves clinical outcomes in patients with high-risk node-positive early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer, based on the mon...
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274 [0.03%]
高危肌层浸润性尿路上皮癌围手术期纳武利尤单抗与安慰剂疗效的5年随访及ctDNA结果：CheckMate 274研究
M D Galsky,J E Gschwend,M I Milowsky et al.
M D Galsky et al.
Background: Despite surgery, recurrence rates remain high in muscle-invasive urothelial carcinoma (MIUC). The phase III randomized, double-blind, multicenter CheckMate 274 trial comparing adjuvant nivolumab versus placebo...
/zaAlectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: Final overall survival analysis of the Phase III ALEX study [0.03%]
Alecensa与克唑替尼用于一线治疗ALK阳性的晚期非小细胞肺癌：III期ALEX研究的最终总生存期分析
S Peters,R Camidge,R Dziadziuszko et al.
S Peters et al.
Background: ALEX, a global, randomized, phase III trial evaluated alectinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer (NSCLC). This final analysis provides mature overall survival...